embryonic stem cell therapy (Mitsubishi Tanabe/Cellartis)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameembryonic stem cell therapy (Mitsubishi Tanabe/Cellartis)
Drug Alias Nameembryonic stem cell therapy (Tanabe/Cell Therapeutics Scandinavia)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Neurogenic potential stem cell therapyCell and gene therapy > Cell therapy > Stem cell therapy > Embryonic stem cells therapy
Mechanisms of ActionNeuroprotectants
TargetsUpdating
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryScandinaviaJapan
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTanabe Seiyaku Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTakara Bio Europe AbTanabe Seiyaku Co Ltd
Active IndicationsN/A
Inactive IndicationsParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A